Lamotrigine Salts, Co-Crystals, and Compositions
AssigneeAzurity Pharmaceuticals Ireland Limited
InventorsJordan R. Hunt, Gerold Mosher, Paras P. Jain, Krishna Mohan Lakshmipathula
Life of this patent
Estimating the term…
Loading patent…
AssigneeAzurity Pharmaceuticals Ireland Limited
InventorsJordan R. Hunt, Gerold Mosher, Paras P. Jain, Krishna Mohan Lakshmipathula
Estimating the term…
The present disclosure relates to novel lamotrigine salts, co-crystals, and compositions. In some embodiments, the lamotrigine salt is a lamotrigine dicarboxylic acid salt or hydrate or solvate thereof. In some embodiments, the lamotrigine co-crystal is a co-crystal of lamotrigine and a dicarboxylic acid, or a hydrate or solvate thereof. In some embodiments, the compositions comprise lamotrigine or a salt or co-crystal thereof, or a hydrate or solvate thereof. In some embodiments, the composition is in the form of a powder. In some embodiments, the composition is in the form of a liquid. The present disclosure also relates to methods of preparation and use in medical therapy, for example, for the treatment of a subject with epilepsy or bipolar disorder.
A stable oral suspension comprising lamotrigine salt or a hydrate or a solvate thereof and one or more pharmaceutically acceptable excipient, wherein the amount of lamotrigine salt or a hydrate or a solvate thereof is equivalent to from 1 mg/mL to 50 mg/mL of lamotrigine (free base), and wherein the stable oral suspension is in the form of a liquid.
A stable oral suspension comprising from 1 mg/mL to 50 mg/mL lamotrigine (free base) and a salting agent, wherein the lamotrigine (free base) forms a lamotrigine salt in situ and wherein the stable oral suspension is in the form of a liquid.
Dependencies are inferred from the claim text.